Pharma and Biotech Daily: Your Essential Industry Update

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Lilly and Novo are leading the pharmaceutical industry with their impressive sales growth of GLP-1 drugs, leaving their competitors in the shadows. Meanwhile, Vir Biotechnology is shifting its focus to immunology following the loss of emergency authorization for its COVID-19 antibody.The shadow market of off-brand versions of GLP-1 drugs is causing regulatory headaches, while Trump's policies continue to impact earnings calls in the pharma sector. Gilead is gearing up for a mid-year launch of lenacapavir, and Novartis has made a major acquisition in a $3.1 billion deal for a blood thinner.In other news, Biogen has secured $250 million from Royalty Pharma for a phase III lupus program, while Lilly is making moves in the mesh and cancer sectors. Inventiva is planning to cut its workforce in half to focus on promising mesh candidates, and Novo executives are working to boost sentiment after a recent error.Stay tuned for more updates in the industry, but remember that job opportunities and other information are always available. For further details, reach out to Annalee Armstrong, senior editor at Biospace. Don't forget to subscribe for a personalized email experience tailored to your preferences.